Company news
Bliss Gvs Pharma Limited (NSE:BLISSGVS) news
Bliss Gvs Pharma Limited news releases on 6ix. Latest, Jul 3, 2026: Bliss GVS Pharma Appoints Rahul Adakmol As CEO Effective July 15, 2026
Press releases & updates
Bliss GVS Pharma Appoints Rahul Adakmol As CEO Effective July 15, 2026
July 3, 2026
IIFL Asset Management picks up nearly 2% stake in Indo Tech Transformers from promoter
June 29, 2026
Buzzing Stocks: John Cockerill up 7% on order win; Bliss GVS hits 52-week high on inspection closure report
June 3, 2026
Bliss GVS Pharma Says Received Inspection Closure Report From World Health Organization
June 2, 2026
Bliss GVS hits 20% upper circuit as Anupam Rasayan to acquire up to 43% stake for Rs 1,369 crore
May 26, 2026
Anupam Rasayan enters formulations business with ₹1,369 cr Bliss GVS Pharma acquisition
May 23, 2026
BLISSGVS: Double-digit revenue and profit growth, strong margins, and expansion in global markets
May 12, 2026
Anupam Rasayan India Denies Plans To Buy Stake In Bliss GVS Pharma
February 13, 2026
BLISSGVS: Q3 FY26 net profit reached ₹2,477.91 lakh; interim dividend of 0.50 paisa per share declared
February 10, 2026
Bliss GVS Pharma board approves appointment of S.N. Kamath as Managing Director
December 23, 2025
Bliss GVS Pharma Incorporates Theralife Pharma In Kenya
November 25, 2025
Bliss GVS Pharma Sept-Quarter Consol Net Profit 272.5 Million Rupees
November 6, 2025
Bliss Gvs Pharma Receives Tax Demand Of 166.9 Million Rupees From Tax Department
October 7, 2025
Bliss GVS Pharma Ltd - Appoints Narsimha Shibroor Kamath As CEO
September 30, 2025
BLISSGVS: Strong Q1 FY26 growth in revenue and profit, with key subsidiary divestment completed
July 30, 2025
Bliss GVS Pharma June-Quarter Consol Net Profit 430.4 Million Rupees
July 29, 2025
Bliss GVS Pharma Gets Show Cause From Tax Department Over Recovery Of Refund Of 66.4 Million Rupees
July 2, 2025
BLISSGVS: Revenue up, net profit down; subsidiary sale and dividend declared, restructuring ahead
May 2, 2025
BLISSGVS: Quarterly revenue and profit grew modestly, with stable performance in core pharma operations
January 28, 2025
BLISSGVS: Revenue and net profit increased, with new leadership and regulatory fine payment noted
October 24, 2024
BLISSGVS: Q1 FY25 saw year-over-year growth in revenue and profit, with improved margins and ESOP activity
July 24, 2024